Clinical Trial Update: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 long-term safety evaluation of tafamidis in transthyretin amyloid cardiomyopathy, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy | Phase 3 | Status: COMPLETED | Results posted: 2025-02-03